港股异动 | 长风药业(02652)涨超17% 肺动脉高压新药IND获受理填补国内治疗PH-ILD领域空白

智通财经03-16

智通财经APP获悉，长风药业(02652)涨超17%，截至发稿，涨16.43%，报26.78港元，成交额1220.58万港元。消息面上，3月13日，长风药业宣布，公司自主研发的治疗肺动脉高压(PAH)及间质性肺疾病相关肺动脉高压(PH-ILD)的吸入粉雾剂ICF001(化学药2.1类改良型新药)，其新药临床试验申请(IND)已获中国国家药品监督管理局(NMPA)正式受理。这是继ICF004之后，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2619487098?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-16 10:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619487098","market":"fut","top_or_hot":-1,"title":"港股异动 | 长风药业(02652)涨超17% 肺动脉高压新药IND获受理 填补国内治疗PH-ILD领域空白","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，长风药业(02652)涨超17%，截至发稿，涨16.43%，报26.78港元，成交额1220.58万港元。消息面上，3月13日，长风药业宣布，公司自主研发的治疗肺动脉高压(PAH)及间质性肺疾病相关肺动脉高压(PH-ILD)的吸入粉雾剂ICF001(化学药2.1类改良型新药)，其新药临床试验申请(IND)已获中国国家药品监督管理局(NMPA)正式受理。这是继ICF004之后，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1414113.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 长风药业(02652)涨超17% 肺动脉高压新药IND获受理 填补国内治疗PH-ILD领域空白</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 长风药业(02652)涨超17% 肺动脉高压新药IND获受理 填补国内治疗PH-ILD领域空白\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-16 10:02 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1414113.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，长风药业(02652)涨超17%，截至发稿，涨16.43%，报26.78港元，成交额1220.58万港元。消息面上，3月13日，长风药业宣布，公司自主研发的治疗肺动脉高压(PAH)及间质性肺疾病相关肺动脉高压(PH-ILD)的吸入粉雾剂ICF001(化学药2.1类改良型新药)，其新药临床试验申请(IND)已获中国国家药品监督管理局(NMPA)正式受理。这是继ICF004之后，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1414113.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1414113.html","article_id":"2619487098","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2619487098","pubTimestamp":1773626554,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，长风药业涨超17%，截至发稿，涨16.43%，报26.78港元，成交额1220.58万港元。消息面上，3月13日，长风药业宣布，公司自主研发的治疗肺动脉高压及间质性肺疾病相关肺动脉高压的吸入粉雾剂ICF001，其新药临床试验申请已获中国国家药品监督管理局正式受理。ICF001的快速推进，有望使其成为国内首个获批用于治疗PH-ILD的吸入药物，填补这一市场空白，同时为全球数十万计的患者带来生命的曙光。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1191":"制药","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","BK4161":"工业机械","IND":"Xtrackers Nifty 500 India ETF","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","BK4580":"工业 4.0","BK4585":"ETF&股票定投概念","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","VXUS":"国际股票ETF-Vanguard","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","PH":"汉尼汾","02652":"长风药业","BK4588":"碎股","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD"},"translate_title":"Changes in Hong Kong stocks | Changfeng Pharmaceutical (02652) rose by more than 17%, the new pulmonary hypertension drug IND was accepted, filling the gap in the domestic treatment of PH-ILD","themeId":"ab62decfe9624416502f0a5b97418c66","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02652":1.5,"PH":1.5,"IND":1.5,"VXUS":1.5},"content_text":"智通财经APP获悉，长风药业(02652)涨超17%，截至发稿，涨16.43%，报26.78港元，成交额1220.58万港元。消息面上，3月13日，长风药业宣布，公司自主研发的治疗肺动脉高压(PAH)及间质性肺疾病相关肺动脉高压(PH-ILD)的吸入粉雾剂ICF001(化学药2.1类改良型新药)，其新药临床试验申请(IND)已获中国国家药品监督管理局(NMPA)正式受理。这是继ICF004之后，公司又一款获得受理的吸入制剂改良型创新药，标志着公司在呼吸系统高端制剂领域的创新研发管线正加速进入收获期。据了解，ICF001是一款基于前药机制实现长效作用的创新型吸入粉雾剂。该类药物在相关罕见及严重肺部疾病中已确立明确的临床价值及验证的重磅药物潜力。尤为值得关注的是，目前国内PH-ILD领域目前尚无任何特效药物获批。ICF001的快速推进，有望使其成为国内首个获批用于治疗PH-ILD的吸入药物，填补这一市场空白，同时为全球数十万计的患者带来生命的曙光。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619487098","isCrawlerRequest":true}

港股异动 | 长风药业(02652)涨超17% 肺动脉高压新药IND获受理 填补国内治疗PH-ILD领域空白

精彩评论

港股异动 | 长风药业(02652)涨超17% 肺动脉高压新药IND获受理填补国内治疗PH-ILD领域空白